DRAVP ID  DRAVPe01776

Peptide Name   FBP

Sequence  RGAHIKGRWKSRCHRF

Sequence Length  16

UniProt ID  No entry found

Taxon ID  None

Source  Synthetic construct

Validation   Experimentally Validated

Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available

Target Organism  SARS-CoV-2

Assay  Plaque reduction assay

Activity 

• [Ref.35259078]A(H1N1)(IC50 = 3.9 μg/ml);A(H3N2)(IC50 = 1.6 μg/ml);FluB (IC50 = 7.1 μg/ml);
• SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 μg/ml);
• SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 μg/ml);
• SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 μg/ml).

Hemolytic Activity 

• [Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC).

Cytotoxicity 

• [Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50 > 1 mg/ml).

Binding Target  membrane

Mechanism  The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters.

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L

Literature 1

Title   Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.

Pubmed ID   35259078

Reference   Emerg Microbes Infect. 2022 Dec;11(1):926-937.

Author   Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.

DOI   10.1080/22221751.2022.2051753